Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus letrozole versus placebo plus letrozole as first-line therapy for advanced hormone receptor-positive breast cancer
2004-000849-38Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Everolimus + letrozole with Placebo + letrozole (2 arms). Primary endpoint: Progression-free survival. Started Jul 2005; status: terminated.
02
Drugs
everolimusletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-000849-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000849-38.